AdultPediatricDosage Forms & Strengths injection, lyophilized powder for reconstitution 120mg/vial 400mg/vial SC solution 200mg/mL single-dose, prefilled syringe or autoinjector Systemic Lupus Erythematosus Indicated for active, autoantibody-positive systemic lupus erythematosus (SLE) in patients who are receiving standard therapy IV Initial: 10 mg/kg IV q2Weeks x 3 doses, THEN Maintenance: 10 mg/kg IV q4Weeks SC 200 mg SC qWeek SC dosing is NOT weight-based If transitioning from IV to SC, administer first SC dose 1-4 weeks after the last IV dose Lupus Nephritis Indicated for active lupus nephritis in patients who are receiving standard therapy IV Initial: 10 mg/kg IV q2Weeks x 3 doses, THEN Maintenance: 10 mg/kg IV q4Weeks SC Initial: 400-mg dose (two 200-mg injections) SC qWeek x 4 doses, THEN Maintenance: 200 mg SC qWeek thereafter Transitioning from IV to SC dosing May transition from IV to SC any time after completing the first 2 IV doses If transitioning, administer first SC dose of 200 mg 1-2 weeks after the last IV dose Dosage Modifications Renal or hepatic impairment: No dosage adjustment recommended for any degree of impairment Dosing Considerations Limitations of use Not evaluated in patients with severe active central nervous system lupus Not studied in combination with other biologics; use not recommended in these situations Dosage Forms & Strengths injection, lyophilized powder for reconstitution 120mg/vial 400mg/vial SC solution 200mg/mL single-dose, prefilled syringe or autoinjector Systemic Lupus Erythematosus Indicated for treatment of patients aged ≥5 years with active, autoantibody-positive, SLE who are receiving standard therapy <5 years: Safety and efficacy not established ≥5 years SC: Safety and efficacy not established in patients <18 years IV Initial: 10 mg/kg IV q2Weeks x 3 doses, THEN Maintenance: 10 mg/kg IV q4Weeks Lupus Nephritis Indicated for active lupus nephritis in patients aged ≥5 years who are receiving standard therapy <5 years: Safety and efficacy not established ≥5 years SC: Safety and efficacy not established in patients <18 years IV Initial: 10 mg/kg IV q2Weeks x 3 doses, THEN Maintenance: 10 mg/kg IV q4Weeks Dosage Modifications Renal or hepatic impairment: No dosage adjustment recommended for any degree of impairment Dosing Considerations Limitations of use Not evaluated in patients with severe active central nervous system lupus Not studied in combination with other biologics; use not recommended in these situations Interaction CheckerEnter a drug name and belimumabNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (34)anthrax vaccine adsorbedbelimumab decreases effects of anthrax vaccine adsorbed by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.BCG vaccine livebelimumab decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.diphtheria & tetanus toxoidsbelimumab decreases effects of diphtheria & tetanus toxoids by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.diphtheria & tetanus toxoids/ acellular pertussis vaccinebelimumab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccinebelimumab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.hepatitis A vaccine inactivatedbelimumab decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.hepatitis a/b vaccinebelimumab decreases effects of hepatitis a/b vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.hepatitis b vaccinebelimumab decreases effects of hepatitis b vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.influenza A (H5N1) vaccinebelimumab decreases effects of influenza A (H5N1) vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.influenza virus vaccine (H5N1), adjuvantedbelimumab decreases effects of influenza virus vaccine (H5N1), adjuvanted by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.influenza virus vaccine quadrivalent, cell-culturedbelimumab decreases effects of influenza virus vaccine quadrivalent, cell-cultured by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.influenza virus vaccine quadrivalent, intranasalbelimumab decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.Japanese encephalitis virus vaccinebelimumab decreases effects of Japanese encephalitis virus vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.measles (rubeola) vaccinebelimumab decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.measles mumps and rubella vaccine, livebelimumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.measles, mumps, rubella and varicella vaccine, livebelimumab decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.meningococcal A C Y and W-135 polysaccharide vaccine combinedbelimumab decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.pneumococcal vaccine 13-valentbelimumab decreases effects of pneumococcal vaccine 13-valent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.pneumococcal vaccine heptavalentbelimumab decreases effects of pneumococcal vaccine heptavalent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.pneumococcal vaccine polyvalentbelimumab decreases effects of pneumococcal vaccine polyvalent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.rabies vaccinebelimumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.rabies vaccine chick embryo cell derivedbelimumab decreases effects of rabies vaccine chick embryo cell derived by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.rotavirus oral vaccine, livebelimumab decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.rubella vaccinebelimumab decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.smallpox (vaccinia) vaccine, livebelimumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.tetanus toxoid adsorbed or fluidbelimumab decreases effects of tetanus toxoid adsorbed or fluid by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.travelers diarrhea and cholera vaccine inactivatedbelimumab decreases effects of travelers diarrhea and cholera vaccine inactivated by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.tuberculin purified protein derivativebelimumab decreases effects of tuberculin purified protein derivative by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.typhoid polysaccharide vaccinebelimumab decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.typhoid vaccine livebelimumab decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.upadacitinibbelimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.varicella virus vaccine livebelimumab decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.yellow fever vaccinebelimumab decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.zoster vaccine livebelimumab decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.Serious - Use Alternative (5)adenovirus types 4 and 7 live, oralbelimumab decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.human papillomavirus vaccine, nonavalentbelimumab decreases effects of human papillomavirus vaccine, nonavalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.human papillomavirus vaccine, quadrivalentbelimumab decreases effects of human papillomavirus vaccine, quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.influenza virus vaccine quadrivalent, adjuvantedbelimumab decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.influenza virus vaccine trivalent, adjuvantedbelimumab decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.Monitor Closely (17)belataceptbelatacept and belimumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.denosumabbelimumab, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.fingolimodbelimumab increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .hydroxyureahydroxyurea, belimumab. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of infection.ifosfamideifosfamide, belimumab. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.influenza virus vaccine quadrivalent, recombinantbelimumab decreases effects of influenza virus vaccine quadrivalent, recombinant by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.influenza virus vaccine trivalent, recombinantbelimumab decreases effects of influenza virus vaccine trivalent, recombinant by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.lomustinelomustine and belimumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.meningococcal group B vaccinebelimumab decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.ofatumumab SCofatumumab SC, belimumab. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.olaparibbelimumab and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity. oxaliplatinoxaliplatin and belimumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections.poliovirus vaccine inactivatedbelimumab decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. .sipuleucel-Tbelimumab decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.trastuzumabtrastuzumab, belimumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .trastuzumab deruxtecantrastuzumab deruxtecan, belimumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or